Preview

Русский журнал детской неврологии

Расширенный поиск

Современные подходы в лечении синдрома Леннокса–Гасто (обзор литературы)

https://doi.org/10.17650/2073-8803-2018-13-2-34-57

Полный текст:

Аннотация

Синдром Леннокса – Гасто (СЛГ) – эпилептическая энцефалопатия с дебютом в детском возрасте, проявляющаяся частыми полиморфными приступами, включая тонические аксиальные, выраженными когнитивными нарушениями, характерными изменениями на электроэнцефалограмме и резистентностью к терапии. Частота синдрома составляет 4–10 % всех форм эпилепсии у детей. Сложности диагностики и лечения СЛГ связаны с сочетанием в картине заболевания приступов нескольких типов, их резистентностью к медикаментозной терапии, возможной эволюцией клинической картины синдрома с возрастом. Авторы представляют обзор литературы, посвященный основным принципам лечения СЛГ, анализ антиэпилептических препаратов, наиболее часто применяемых при этом заболевании, подробно рассматривают клинические исследования, в которых были получены доказательства эффективности и переносимости антиэпилептических препаратов при данной форме эпилепсии. Статья содержит подробный алгоритм лечения СЛГ, основанный на международных рекомендациях и мнениях экспертов.

Об авторах

К. Ю. Мухин
ООО «Институт детской неврологии и эпилепсии им. Святителя Луки»
Россия

Константин Юрьевич Мухин 

108840 Москва, Троицк, ул. Нагорная, 5



О. А. Пылаева
ООО «Институт детской неврологии и эпилепсии им. Святителя Луки»
Россия
108840 Москва, Троицк, ул. Нагорная, 5


Список литературы

1. Инструкция по применению лекарственного препарата для медицинского применения Иновелон.

2. Карлов В.А. Эпилепсия с преобладанием приступов падения. В кн.: Эпилепсия у детей и взрослых женщин и мужчин. М.: Медицина, 2010. С. 167–173.

3. Мухин К.Ю., Миронов М.Б. Клинические, электроэнцефалографические и нейровизуализационные характеристики эпилептических синдромов, ассоциированных с тоническими приступами. Русский журнал детской неврологии 2014;9(3):13–22.

4. Мухин К.Ю., Петрухин А.С., Калашникова Н.Б. Современные представления о детской эпилептической энцефалопатии с диффузными медленными пик-волнами на ЭЭГ (синдром Леннокса–Гасто): учебно-методическое пособие. М., 2002. 72 c. .

5. Пылаева О.А., Мухин К.Ю., Петрухин А.С. Побочные эффекты антиэпилептической терапии. М.: Гранат, 2016. 236 с.

6. Темин П.А., Никанорова М.Ю., Крапивкин А.И. и др. Синдром Леннокса– Гасто. В кн.: Диагностика и лечение эпилепсий у детей. М.: Можайск-Терра, 1997. С. 355–368.

7. Aicardi J., Levy Gomes A. The Lennox– Gastaut syndrome: clinical and electroencephalographic features. In: The Lennox– Gastaut syndrome. Eds.: E. Niedermeyer, R. Degen. New York: Alan R. Liss, Inc., 1988. Pр. 25–46.

8. Al-Banji M.H., Zahr D.K., Jan M.M. Lennox–Gastaut syndrome. Management update. Neurosciences (Riyadh) 2015;20(3):207–12. PMID: 26166587. DOI: 10.17712/nsj.2015.3.20140677.

9. Albini M., Morano A., Fanella M. et al. Effectiveness of rufinamide in the treatment of idiopathic generalized epilepsy with atypical evolution: case report and review of the literature. Clin EEG Neurosci 2016;47(2):162–6. DOI: 10.1177/1550059414559940.

10. Alsaad A.M., Koren G. Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials. Br J Clin Pharmacol 2014;78(6):1264–71. PMID: 25132372. DOI: 10.1111/bcp.12479.

11. Arzimanoglou A., French J., Blume W.T. et al. Lennox–Gastaut syndrome: a consensus approach on diagnosis, assessment, management and trial methodology. Lancet Neurol 2009;8(1):82–93. PMID: 19081517. DOI: 10.1016/S14744422(08)70292-8.

12. Arzimanoglou A., Resnick T. Diagnosing and treating epileptic drop attacks, atypical absences and episodes of nonconvulsive status epilepticus. Epileptic Disord 2011;13(Suppl 1):S1–2. PMID: 21436013. DOI: 10.1684/epd.2011.0408.

13. Beaumanoir A., Dravet Ch. The Lennox– Gastaut syndrome. In: Epileptic syndromes in infancy, childhood and adolescence. 2nd edn. Eds.: J. Roger, M. Bureau, Ch. Dravet et al. London: John Libbey, 1992. Pр. 307–312.

14. Blume W.T. Pathogenesis of Lennox– Gastaut syndrome: considerations and hypotheses. Epileptic Disord. 2001;3(4):183–196.

15. Brodie M.J., Rosenfeld W.E., Vazquez B. et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009;50(8):1899–909. PMID: 19490053. DOI: 10.1111/j.1528-1167.2009.02160.x.

16. Conry J.A., Ng Y.T., Kernitsky L. et al. Stable dosages of clobazam for Lennox– Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia 2014;55(4):558–67. PMID: 24580023 . DOI: 10.1111/epi.12561.

17. Conry J.A., Ng Y.T., Paolicchi J.M. et al. Clobazam in the treatment of Lennox– Gastaut syndrome. Epilepsia 2009;50(5):1158–66. PMID: 19170737. DOI: 10.1111/j.1528-1167.2008.01935.x.

18. Coppola G., Besag F., Cusmai R. et al. Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines. Eur J Paediatr Neurol 2014;18(6):685–90. DOI: 10.1016/j.ejpn.2014.05.008.

19. Coppola G., Grosso S., Franzoni E. et al. Rufinamide in children and adults with Lennox–Gastaut syndrome: first Italian multicenter experience. Seizure 2010;19(9):587–91. DOI: 10.1016/j.seizure.2010.09.008.

20. Coppola G. Update on rufinamide in childhood epilepsy. Neuropsychiatr Dis Treat 2011;7:399–407. PMID: 21792306. DOI: 10.2147/NDT.S13910.

21. Cortez M.A., McKerlie C., Snead O.C. A model of atypical absence seizures: EEG, pharmacology and developmental characterization. Neurology 2001;56(3): 341–349. PMID: 11171899.

22. Cross J.H., Auvin S., Falip M. et al. Expert opinion on the management of Lennox– Gastaut syndrome: treatment algorithms and practical considerations. Front Neurol 2017;8:505. PMID: 29085326. DOI: 10.3389/fneur.2017.00505.

23. Depienne C., Gourfinkel-An I., Baulac S., LeGuern E. Genes in infantile epileptic encephalopathies. 4th edn. In: Jasper’s Basic Mechanisms of the Epilepsies. Eds.: J.L. Noebels, M. Avoli, M.A. Rogawski et al. Bethesda: National Center for Biotechnology Information, 2012. Pp. 1187–1210.

24. Dodson W.E. Felbamate in the treatment of Lennox–Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia 1993;34(Suppl 7):S18–24. DOI: 10.1111/j.1528-1157.1993.tb04590.x.

25. Duncan J.S, Shorvon S.D., Trimble M.R. Discontinuation of phenytoin, carbamazepine, and valproate in patients with active epilepsy. Epilepsia 1990;31(3):324–33. PMID: 2111768.

26. Epilepsies: diagnosis and management (2012, updated in 2016). NICE guideline CG137. Available at: http://www.nice.org.uk/guidance/CG137.

27. Epilepsy Phenome/Genome Project Epi4K Consortium. Copy number variant analysis from exome data in 349 patients with epileptic encephalopathy. Ann Neurol 2015;78(2):323–8. PMID: 26068938. DOI: 10.1002/ana.24457.

28. Eriksson A.S., Nergårdh A., Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia 1998;39(5):495– 501. PMID: 9596201.

29. EuroEPINOMICS-RES Consortium, Epilepsy Phenome/Genome Project, Epi4K Consortium. De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. Am J Hum Genet 2014;95(4):360–70. PMID: 25262651. DOI: 10.1016/j.ajhg.2014.08.013.

30. Ferlazzo E., Adjien C.K., Guerrini R. et al. Lennox–Gastaut syndrome with late-onset and prominent reflex seizures in trisomy 21 patients. Epilepsia 2009;50(6):1587–95. PMID: 19187280. DOI: 10.1111/j.1528-1167.2008.01944.x.

31. Gastaut H., Roger J., Soulayrol R. et al. Childhood epileptic encephalopathy with diffuse slow spike-waves (otherwise known as “petit mal variant”) or Lennox syndrome. Epilepsia 1966;7(2):139–79. PMID: 4959714.

32. Genton P., Dravet Ch. The Lennox– Gastaut syndrome. In: Comprehensive еpileptology. 2nd edn. Eds.: J. Engel, T.A. Pedley. Philadelphia: Lippincott-Raven, 2007. Pр. 2417–2427.

33. Glauser T., Kluger G., Sachdeo R. et al. Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome. Neurology 2008;70(21):1950–8. DOI: 10.1212/01.wnl.0000303813.95800.0d.

34. Glauser T.A., Levisohn P.M., Ritter F., Sachdeo R.C. Topiramate in Lennox– Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia 2000;41(Suppl 1):S86–90. DOI: 10.1111/j.1528-1157.2000.tb01563.x.

35. Guerrini R., Marini C. Epileptic еncephalopathies. In: Epilepsy and еpileptic seizures. Eds.: S. Shorvon, R. Guerrini, M. Cook, S. Lhatoo. London: Oxford University Press, 2013. Pр. 177–180.

36. Hancock E.C., Cross J.H. Treatment of Lennox–Gastaut syndrome. Cochrane Database Syst Rev 2013;2:CD003277. DOI: 10.1002/14651858.CD003277.

37. Holthausen H., Piper T., Winkler P. et al. Electro-clinical-pathological correlations in focal cortical dysplasia (FCD) at young ages. Childs Nerv Syst 2014;30(12):2015– 26. PMID: 25255773. DOI: 10.1007/s00381-014-2549-6.

38. Hsieh D.T., Thiele E.A. Efficacy and safety of rufinamide in pediatric epilepsy. Ther Adv Neurol Disord 2013;6(3): 189–98. PMID: 23634191. DOI: 10.1177/1756285613481083.

39. Hughes J.R., Patil V.K. Long-term electroclinical changes in the Lennox–Gastaut syndrome before, during and after the slow spike-wave pattern. Clin Electroencephalogr 2002;33(1):1–7. PMID: 11795207.

40. Kayani S., Sirsi D. The safety and tolerability of newer antiepileptic drugs in children and adolescents. J Cent Nerv Syst Dis 2012;4:51–63. PMID: 23650467. DOI: 10.4137/JCNSD.S5097.

41. Kerr M., Kluger G., Philip S. Evolution and management of Lennox–Gastaut syndrome through adolescence and into adulthood: are seizures always the primary issue? Epileptic Disord 2011;13(Suppl 1): S15–S26. PMID: 21669559. DOI: 10.1684/epd.2011.0409.

42. Kessler S.K., McCarthy A., Cnaan A., Dlugos D.J. Retention rates of rufinamide in pediatric epilepsy patients with and without Lennox–Gastaut Syndrome. Epilepsy Res 2015;112:18–26. PMID: 25847334. DOI: 10.1016/j.eplepsyres.2015.02.003.

43. Kim J.Y., Lee C.G., Yu H.J. et al. The efficacy and tolerability of rufinamide in intractable pediatric epilepsy. J Epilepsy Res 2012;2(2):33–7. PMID: 24649460. DOI: 10.14581/jer.12009.

44. Kluger G., Haberlandt E., Kurlemann G. et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav 2010;17(4):546–8. PMID: 20185372. DOI: 10.1016/j.yebeh.2010.01.005.

45. Kluger G., Glauser T., Krauss G. et al. Adjunctive rufinamide in Lennox–Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand 2010;122(3):202–8. PMID: 20199521. DOI: 10.1111/j.1600-0404.2010.01334.x.

46. Kluger G., Bauer B. Role of rufinamide in the management of Lennox–Gastaut syndrome (childhood epileptic encephalopathy). Neuropsychiatr Dis Treat 2007;3(1):3–11. PMID: 19300535.

47. Larsen J., Johannesen K.M., Ek J. et al. The role of SLC2A1 mutations in myoclonic astatic epilepsy and absence epilepsy, and the estimated frequency of GLUT1 deficiency syndrome. Epilepsia 2015;56(12):e203–8. PMID: 26537434. DOI: 10.1111/epi.13222.

48. Lee E.H., Yum M.S., Choi H.W., Ko T.S. Long-term use of clobazam in Lennox– Gastaut syndrome: experience in a single tertiary epilepsy center. Clin Neuropharmacol 2013;36(1):4–7. PMID: 23334068. DOI: 10.1097/WNF.0b013e3182770730.

49. Lee E.H., Yum M.S., Ko T.S. Effectiveness and tolerability of rufinamide in children and young adults with Lennox–Gastaut syndrome: a single center study in Korea. Clin Neurol Neurosurg 2013;115(7):926–9. PMID: 23083943. DOI: 10.1016/j.clineuro.2012.09.021.

50. Liao W.P., Shi Y.W., Long Y.S. et al. Partial epilepsy with antecedent febrile seizures and seizure aggravation by antiepileptic drugs: associated with loss of function of Na(v) 1.1. Epilepsia 2010;51(9): 1669–78. PMID: 20550552. DOI: 10.1111/j.1528-1167.2010.02645.x.

51. McMurray R., Striano P. Treatment of adults with Lennox–Gastaut syndrome: further analysis of efficacy and safety/ tolerability of rufinamide. Neurol Ther 2016;5(1):35–43. PMID: 26861566. DOI: 10.1007/s40120-016-0041-9.

52. Montouris G.D., Wheless J.W., Glauser T.A. The efficacy and tolerability of pharmacologic treatment options for Lennox– Gastaut syndrome. Epilepsia 2014;55 (Suppl 4):10–20. PMID: 25284033. DOI: 10.1111/epi.12732.

53. Motte J., Trevathan E., Arvidsson J.F. et al. Lamotrigine for generalized seizures associated with the Lennox–Gastaut syndrome. N Engl J Med 1997;337(25):1807–12. DOI: 10.1056/NEJM199712183372504.

54. Mourand I., Crespel A., Gelisse P. Dramatic weight loss with rufinamide. Epilepsia 2013;54(1):e5–8. PMID: 22780580. DOI: 10.1111/j.1528-1167.2012.03579.x.

55. Ng Y.T., Conry J.A., Drummond R. et al. Randomized, phase III study results of clobazam in Lennox–Gastaut syndrome. Neurology 2011;77(15):1473–81. PMID: 21956725. DOI: 10.1212/WNL.0b013e318232de76.

56. Oguni H., Uehara T., Tanaka T. et al. Dramatic effect of ethosuximide on epileptic negative myoclonus: implications for the neurophysiological mechanism. Neuropediatrics 1998;29(1):29–34. PMID: 9553946. DOI: 10.1055/s-2007-973530.

57. Ohtsuka Y., Yoshinaga H., Shirasaka Y. et al. Long-term safety and seizure outcome in Japanese patients with Lennox–Gastaut syndrome receiving adjunctive rufinamide therapy: an open-label study following a randomized clinical trial. Epilepsy Res 2016;121:1–7. PMID: 26827266. DOI: 10.1016/j.eplepsyres.2016.01.002.

58. Ohtsuka Y., Yoshinaga H., Shirasaka Y. et al. Rufinamide as an adjunctive therapy for Lennox–Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Res 2014;108(9):1627–36. PMID: 25219353. DOI: 10.1016/j.eplepsyres.2014.08.019.

59. Ostendorf A.P., Ng Y.T. Treatmentresistant Lennox–Gastaut syndrome: therapeutic trends, challenges and future directions. Neuropsychiatr Dis Treat 2017;13:1131–40. PMID: 28461749. DOI: 10.2147/NDT.S115996.

60. Palhagen S., Canger R., Henriksen O. et al. Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsy Res 2001;43(2):115–24. PMID: 11164700.

61. Panayiotopoulos C.P. A clinical guide to epileptic syndromes and their treatment: based on the ILAE Classifications and Practice Parameter Guidelines. 2nd edn. London: Springer, 2010. 578 p.

62. Panayotopoulos С.P. Principles of therapy in the epilepsies. In: A clinical guide to epileptic syndromes and their treatment. London: Springer, 2007. Pp. 155–184.

63. Sachdeo R.C., Glauser T.A., Ritter F. et al. A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome. Neurology 1999;52(9):1882–7. DOI: 10.1212/WNL.52.9.1882.

64. Sankar R., Chung S., Perry M.S. et al. Clinical considerations in transitioning patients with epilepsy from clonazepam to clobazam: a case series. J Med Case Reports 2014;8:429. PMID: 25511520. DOI: 10.1186/1752-1947-8-429.

65. Snead O.C., Hosey L.C. Treatment of epileptic falling spells with ethosuximide. Brain Dev 1987;9(6): 602–4. PMID: 3445921.

66. The Felbamate Study Group in Lennox– Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox–Gastaut syndrome). N Engl J Med 1993;328(1):29–33. DOI: 10.1056/NEJM199301073280105.

67. Thome-Souza S., Kadish N.E., Ramgopal S. et al. Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience. Epilepsia 2014;55(8):1235–44. PMID: 25070475. DOI: 10.1111/epi.12689.

68. Tomson T., Marson A., Boon P. et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia 2015;56(7):1006–19. DOI: 10.1111/epi.13021.

69. Verrotti A., Loiacono G., Ballone E. et al. Efficacy of rufinamide in drug-resistant epilepsy: a meta-analysis. Pediatr Neurol 2011;44(5):347–9. PMID: 21481742. DOI: 10.1016/j.pediatrneurol.2010.12.005.

70. Verrotti A., Loiacono G., Rossi A. et al. Successful treatment of refractory seizures with rufinamide in children with schizencephaly: report of 3 cases. J Child Neurol 2015;30(8):1079–83. DOI: 10.1177/0883073814542951.

71. Wheless J.W., Clarke D.F., Arzimanoglou A., Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 2007;9(4):353–412. PMID: 18077226. DOI: 10.1684/epd.2007.0144.

72. Wheless J.W., Clarke D.F., Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol 2005;20(Suppl 1):S1–56. PMID: 16615562. DOI: 10.1177/088307380502000101.

73. Wheless J. W., Conry J., Krauss G. et al. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol 2009;24(12):1520–5. PMID: 19955344. DOI: 10.1177/0883073809350508.

74. Wier H.A., Cerna A., So T.Y. Rufinamide for pediatric patients with Lennox– Gastaut syndrome: a comprehensive overview. Paediatric Drugs 2011;13(2):97–106. PMID: 21351809. DOI: 10.2165/11586920-00000000000000.


Для цитирования:


Мухин К.Ю., Пылаева О.А. Современные подходы в лечении синдрома Леннокса–Гасто (обзор литературы). Русский журнал детской неврологии. 2018;13(2):34-57. https://doi.org/10.17650/2073-8803-2018-13-2-34-57

For citation:


Мukhin К.Y., Pylaeva О.A. Modern approaches in the treatment of Lennox–gastaut syndrome (a review of literature). Russian Journal of Child Neurology. 2018;13(2):34-57. (In Russ.) https://doi.org/10.17650/2073-8803-2018-13-2-34-57

Просмотров: 46


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2073-8803 (Print)
ISSN 2412-9178 (Online)